Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

RNA-binding protein EWS (EWS oncogene) (Ewing sarcoma breakpoint region 1 protein)

 EWS_HUMAN               Reviewed;         656 AA.
Q01844; B0QYK1; Q5THL0; Q92635; Q96FE8; Q96MN4; Q96MX4; Q9BWA2;
01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
01-JUN-1994, sequence version 1.
25-OCT-2017, entry version 204.
RecName: Full=RNA-binding protein EWS;
AltName: Full=EWS oncogene;
AltName: Full=Ewing sarcoma breakpoint region 1 protein;
Name=EWSR1; Synonyms=EWS;
Homo sapiens (Human).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
Catarrhini; Hominidae; Homo.
NCBI_TaxID=9606;
[1]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM EWS), INVOLVEMENT IN EWS, AND
CHROMOSOMAL TRANSLOCATION WITH FLI.
TISSUE=Fetal brain;
PubMed=1522903; DOI=10.1038/359162a0;
Delattre O., Zucman J., Plougastel B., Desmaze C., Melot T., Peter M.,
Kovar H., Joubert I., de Jong P., Rouleau G., Aurias A., Thomas G.;
"Gene fusion with an ETS DNA-binding domain caused by chromosome
translocation in human tumours.";
Nature 359:162-165(1992).
[2]
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
PubMed=8307570; DOI=10.1016/S0888-7543(05)80363-5;
Plougastel B., Zucman J., Peter M., Thomas G., Delattre O.;
"Genomic structure of the EWS gene and its relationship to EWSR1, a
site of tumor-associated chromosome translocation.";
Genomics 18:609-615(1993).
[3]
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
Zucman-Rossi J., Legoix P., Thomas G.;
"Genomic sequence of the human EWS gene with the 5' flanking region.";
Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
[4]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
Beare D.M., Dunham I.;
"A genome annotation-driven approach to cloning the human ORFeome.";
Genome Biol. 5:R84.1-R84.11(2004).
[5]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 5 AND 6).
PubMed=14702039; DOI=10.1038/ng1285;
Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
"Complete sequencing and characterization of 21,243 full-length human
cDNAs.";
Nat. Genet. 36:40-45(2004).
[6]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
PubMed=10591208; DOI=10.1038/990031;
Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
Khan A.S., Lane L., Tilahun Y., Wright H.;
"The DNA sequence of human chromosome 22.";
Nature 402:489-495(1999).
[7]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
Venter J.C.;
Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
[8]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS EWS; 3 AND 4).
TISSUE=Lymph, Muscle, Placenta, and Skin;
PubMed=15489334; DOI=10.1101/gr.2596504;
The MGC Project Team;
"The status, quality, and expansion of the NIH full-length cDNA
project: the Mammalian Gene Collection (MGC).";
Genome Res. 14:2121-2127(2004).
[9]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-345.
PubMed=8975699; DOI=10.1006/geno.1996.0625;
Zucman-Rossi J., Legoix P., Thomas G.;
"Identification of new members of the Gas2 and Ras families in the
22q12 chromosome region.";
Genomics 38:247-254(1996).
[10]
PROTEIN SEQUENCE OF 128-158; 233-247; 268-324; 334-364; 393-439;
447-518 AND 551-641, METHYLATION AT ARG-300; ARG-302; ARG-304;
ARG-309; ARG-314; ARG-317; ARG-321; ARG-455; ARG-464; ARG-471;
ARG-490; ARG-494; ARG-500; ARG-503; ARG-506; ARG-563; ARG-565;
ARG-572; ARG-575; ARG-581; ARG-589; ARG-592; ARG-596; ARG-600;
ARG-603; ARG-607; ARG-615; ARG-633 AND ARG-636, AND IDENTIFICATION BY
MASS SPECTROMETRY.
PubMed=11278906; DOI=10.1074/jbc.M011446200;
Belyanskaya L.L., Gehrig P.M., Gehring H.;
"Exposure on cell surface and extensive arginine methylation of Ewing
sarcoma (EWS) protein.";
J. Biol. Chem. 276:18681-18687(2001).
[11]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 241-268.
TISSUE=Placenta;
PubMed=7542907; DOI=10.1002/gcc.2870130209;
Bhagirath T., Abe S., Nojima T., Yoshida M.C.;
"Molecular analysis of a t(11;22) translocation junction in a case of
Ewing's sarcoma.";
Genes Chromosomes Cancer 13:126-132(1995).
[12]
PROTEIN SEQUENCE OF 269-292; 393-404; 411-439; 491-500 AND 615-632,
METHYLATION AT ARG-494 AND ARG-615, AND IDENTIFICATION BY MASS
SPECTROMETRY.
TISSUE=Colon carcinoma, and Ovarian carcinoma;
Bienvenut W.V., Lilla S., von Kriegsheim A., Lempens A., Zebisch A.,
Kolch W.;
Submitted (DEC-2008) to UniProtKB.
[13]
PARTIAL PROTEIN SEQUENCE, AND PHOSPHORYLATION AT SER-266.
PubMed=9341188; DOI=10.1074/jbc.272.43.27369;
Deloulme J.C., Prichard L., Delattre O., Storm D.R.;
"The prooncoprotein EWS binds calmodulin and is phosphorylated by
protein kinase C through an IQ domain.";
J. Biol. Chem. 272:27369-27377(1997).
[14]
CHROMOSOMAL TRANSLOCATION WITH ATF1.
PubMed=8401579; DOI=10.1038/ng0893-341;
Zucman J., Delattre O., Desmaze C., Epstein A.L., Stenman G.,
Speleman F., Fletchers C.D., Aurias A., Thomas G.;
"EWS and ATF-1 gene fusion induced by t(12;22) translocation in
malignant melanoma of soft parts.";
Nat. Genet. 4:341-345(1993).
[15]
ALTERNATIVE SPLICING, AND RNA-BINDING.
PubMed=8084618;
Ohno T., Ouchida M., Lee L., Gatalica Z., Rao V.N., Reddy E.S.P.;
"The EWS gene, involved in Ewing family of tumors, malignant melanoma
of soft parts and desmoplastic small round cell tumors, codes for an
RNA binding protein with novel regulatory domains.";
Oncogene 9:3087-3097(1994).
[16]
CHROMOSOMAL TRANSLOCATION WITH NR4A3.
PubMed=7539287; DOI=10.1002/gcc.2870120412;
Gill S., McManus A.P., Crew A.J., Benjamin H., Sheer D.,
Gusterson B.A., Pinkerton C.R., Patel K., Cooper C.S., Shipley J.M.;
"Fusion of the EWS gene to a DNA segment from 9q22-31 in a human
myxoid chondrosarcoma.";
Genes Chromosomes Cancer 12:307-310(1995).
[17]
CHROMOSOMAL TRANSLOCATION WITH ETV1.
PubMed=7700648;
Jeon I.-S., Davis J.N., Braun B.S., Sublett J.E., Roussel M.F.,
Denny C.T., Shapiro D.N.;
"A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to
the ETS gene ETV1.";
Oncogene 10:1229-1234(1995).
[18]
CHROMOSOMAL TRANSLOCATION WITH WT1.
PubMed=7862627; DOI=10.1073/pnas.92.4.1028;
Gerald W.L., Rosai J., Ladanyi M.;
"Characterization of the genomic breakpoint and chimeric transcripts
in the EWS-WT1 gene fusion of desmoplastic small round cell tumor.";
Proc. Natl. Acad. Sci. U.S.A. 92:1028-1032(1995).
[19]
INVOLVEMENT IN EWS, AND CHROMOSOMAL TRANSLOCATION WITH FEV.
PubMed=9121764; DOI=10.1038/sj.onc.1200933;
Peter M., Couturier J., Pacquement H., Michon J., Thomas G.,
Magdelenat H., Delattre O.;
"A new member of the ETS family fused to EWS in Ewing tumors.";
Oncogene 14:1159-1164(1997).
[20]
INTERACTION WITH SF1.
PubMed=9660765; DOI=10.1074/jbc.273.29.18086;
Zhang D., Paley A.J., Childs G.;
"The transcriptional repressor ZFM1 interacts with and modulates the
ability of EWS to activate transcription.";
J. Biol. Chem. 273:18086-18091(1998).
[21]
CHARACTERIZATION.
PubMed=10767297; DOI=10.1074/jbc.M002961200;
Li K.K.C., Lee K.A.W.;
"Transcriptional activation by the Ewing's sarcoma (EWS) oncogene can
be cis-repressed by the EWS RNA-binding domain.";
J. Biol. Chem. 275:23053-23058(2000).
[22]
CHROMOSOMAL TRANSLOCATION WITH PATZ1.
PubMed=10949935; DOI=10.1038/sj.onc.1203762;
Mastrangelo T., Modena P., Tornielli S., Bullrich F., Testi A.,
Mezzelani A., Radice P., Azzarelli A., Pilotti S., Croce C.,
Pierotti M., Sozzi G.;
"A novel zinc finger gene is fused to EWS in small round cell tumor.";
Oncogene 19:3799-3804(2000).
[23]
CHROMOSOMAL TRANSLOCATION WITH ERG, CHROMOSOMAL TRANSLOCATION WITH
FLI1, AND INVOLVEMENT IN EWS.
PubMed=15044653; DOI=10.1056/NEJMc032965;
Bielack S.S., Paulussen M., Koehler G.;
"A patient with two Ewing's sarcomas with distinct EWS fusion
transcripts.";
N. Engl. J. Med. 350:1364-1365(2004).
[24]
CHARACTERIZATION OF THE EWSR1-FEV FUSION PROTEIN.
PubMed=17172842; DOI=10.4161/cc.5.23.3505;
Braunreiter C.L., Hancock J.D., Coffin C.M., Boucher K.M.,
Lessnick S.L.;
"Expression of EWS-ETS fusions in NIH3T3 cells reveals significant
differences to Ewing's sarcoma.";
Cell Cycle 5:2753-2759(2006).
[25]
SUBCELLULAR LOCATION, NUCLEAR LOCALIZATION SIGNAL, AND MUTAGENESIS OF
ARG-648; ARG-651; ARG-652; ASP-653; ARG-654; PRO-655 AND TYR-656.
PubMed=16965792; DOI=10.1016/j.jmb.2006.08.018;
Zakaryan R.P., Gehring H.;
"Identification and characterization of the nuclear
localization/retention signal in the EWS proto-oncoprotein.";
J. Mol. Biol. 363:27-38(2006).
[26]
INTERACTION WITH TDRD3.
PubMed=18632687; DOI=10.1093/hmg/ddn203;
Goulet I., Boisvenue S., Mokas S., Mazroui R., Cote J.;
"TDRD3, a novel Tudor domain-containing protein, localizes to
cytoplasmic stress granules.";
Hum. Mol. Genet. 17:3055-3074(2008).
[27]
METHYLATION AT ARG-490; ARG-572; ARG-596; ARG-603 AND ARG-607.
PubMed=18320585; DOI=10.1002/prot.22004;
Pahlich S., Zakaryan R.P., Gehring H.;
"Identification of proteins interacting with protein arginine
methyltransferase 8: the Ewing sarcoma (EWS) protein binds independent
of its methylation state.";
Proteins 72:1125-1137(2008).
[28]
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
TISSUE=Cervix carcinoma;
PubMed=20068231; DOI=10.1126/scisignal.2000475;
Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
Mann M.;
"Quantitative phosphoproteomics reveals widespread full
phosphorylation site occupancy during mitosis.";
Sci. Signal. 3:RA3-RA3(2010).
[29]
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
PubMed=21269460; DOI=10.1186/1752-0509-5-17;
Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
"Initial characterization of the human central proteome.";
BMC Syst. Biol. 5:17-17(2011).
[30]
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
TISSUE=Liver;
PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
Wang L., Ye M., Zou H.;
"An enzyme assisted RP-RPLC approach for in-depth analysis of human
liver phosphoproteome.";
J. Proteomics 96:253-262(2014).
[31]
METHYLATION [LARGE SCALE ANALYSIS] AT ARG-471; ARG-486 AND ARG-615,
AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
TISSUE=Colon carcinoma;
PubMed=24129315; DOI=10.1074/mcp.O113.027870;
Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V.,
Aguiar M., Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C.,
Vemulapalli V., Bedford M.T., Comb M.J.;
"Immunoaffinity enrichment and mass spectrometry analysis of protein
methylation.";
Mol. Cell. Proteomics 13:372-387(2014).
[32]
STRUCTURE BY NMR OF 353-453.
RIKEN structural genomics initiative (RSGI);
"Solution structure of the RNA recognition motif of Ewing sarcoma
(EWS) protein.";
Submitted (NOV-2005) to the PDB data bank.
[33]
CHROMOSOMAL TRANSLOCATION WITH ATF1, AND INVOLVEMENT IN AFH.
PubMed=15884099; DOI=10.1002/gcc.20201;
Hallor K.H., Mertens F., Jin Y., Meis-Kindblom J.M., Kindblom L.-G.,
Behrendtz M., Kalen A., Mandahl N., Panagopoulos I.;
"Fusion of the EWSR1 and ATF1 genes without expression of the MITF-M
transcript in angiomatoid fibrous histiocytoma.";
Genes Chromosomes Cancer 44:97-102(2005).
[34]
CHROMOSOMAL TRANSLOCATION WITH CREB1, AND INVOLVEMENT IN AFH.
PubMed=17724745; DOI=10.1002/gcc.20491;
Antonescu C.R., Dal Cin P., Nafa K., Teot L.A., Surti U.,
Fletcher C.D., Ladanyi M.;
"EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous
histiocytoma.";
Genes Chromosomes Cancer 46:1051-1060(2007).
-!- FUNCTION: Might normally function as a transcriptional repressor.
EWS-fusion-proteins (EFPS) may play a role in the tumorigenic
process. They may disturb gene expression by mimicking, or
interfering with the normal function of CTD-POLII within the
transcription initiation complex. They may also contribute to an
aberrant activation of the fusion protein target genes.
-!- SUBUNIT: Binds POLR2C, SF1, calmodulin and RNA. Interacts with
PTK2B/FAK2 and TDRD3. Binds calmodulin in the presence, but not in
the absence, of calcium ion. {ECO:0000269|PubMed:18632687,
ECO:0000269|PubMed:9660765}.
-!- INTERACTION:
Self; NbExp=3; IntAct=EBI-739737, EBI-739737;
Q8N5M1:ATPAF2; NbExp=6; IntAct=EBI-739737, EBI-1166928;
Q09472:EP300; NbExp=2; IntAct=EBI-739737, EBI-447295;
P35637:FUS; NbExp=5; IntAct=EBI-739737, EBI-400434;
Q92993:KAT5; NbExp=2; IntAct=EBI-739737, EBI-399080;
Q8NDC0:MAPK1IP1L; NbExp=5; IntAct=EBI-739737, EBI-741424;
Q9UBV8:PEF1; NbExp=3; IntAct=EBI-739737, EBI-724639;
O15162:PLSCR1; NbExp=4; IntAct=EBI-739737, EBI-740019;
Q99873:PRMT1; NbExp=2; IntAct=EBI-739737, EBI-78738;
Q9NZ81:PRR13; NbExp=3; IntAct=EBI-739737, EBI-740924;
Q9NS23-2:RASSF1; NbExp=3; IntAct=EBI-739737, EBI-438698;
O95486:SEC24A; NbExp=3; IntAct=EBI-739737, EBI-749911;
O94855:SEC24D; NbExp=3; IntAct=EBI-739737, EBI-748817;
Q9BWW4:SSBP3; NbExp=3; IntAct=EBI-739737, EBI-2902395;
Q92734:TFG; NbExp=3; IntAct=EBI-739737, EBI-357061;
Q13077:TRAF1; NbExp=3; IntAct=EBI-739737, EBI-359224;
Q12933:TRAF2; NbExp=3; IntAct=EBI-739737, EBI-355744;
P49910:ZNF165; NbExp=2; IntAct=EBI-739737, EBI-741694;
-!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:16965792}.
Cytoplasm {ECO:0000269|PubMed:16965792}. Cell membrane
{ECO:0000269|PubMed:16965792}. Note=Relocates from cytoplasm to
ribosomes upon PTK2B/FAK2 activation.
-!- ALTERNATIVE PRODUCTS:
Event=Alternative splicing; Named isoforms=6;
Name=EWS;
IsoId=Q01844-1; Sequence=Displayed;
Name=EWS-B;
IsoId=Q01844-2; Sequence=VSP_005793;
Note=No experimental confirmation available.;
Name=3;
IsoId=Q01844-3; Sequence=VSP_043453;
Name=4;
IsoId=Q01844-4; Sequence=VSP_043452, VSP_043454;
Note=No experimental confirmation available.;
Name=5;
IsoId=Q01844-5; Sequence=VSP_043451, VSP_043453;
Note=No experimental confirmation available.;
Name=6;
IsoId=Q01844-6; Sequence=VSP_045412;
Note=No experimental confirmation available.;
-!- TISSUE SPECIFICITY: Ubiquitous.
-!- DOMAIN: EWS activation domain (EAD) functions as a potent
activation domain in EFPS. EWSR1 binds POLR2C but not POLR2E or
POLR2G, whereas the isolated EAD binds POLR2E and POLR2G but not
POLR2C. Cis-linked RNA-binding domain (RBD) can strongly and
specifically repress trans-activation by the EAD.
-!- PTM: Phosphorylated; calmodulin-binding inhibits phosphorylation
of Ser-266. {ECO:0000269|PubMed:9341188}.
-!- PTM: Highly methylated on arginine residues. Methylation is
mediated by PRMT1 and, at lower level by PRMT8.
{ECO:0000269|PubMed:11278906, ECO:0000269|PubMed:18320585,
ECO:0000269|Ref.12}.
-!- DISEASE: Ewing sarcoma (ES) [MIM:612219]: A highly malignant,
metastatic, primitive small round cell tumor of bone and soft
tissue that affects children and adolescents. It belongs to the
Ewing sarcoma family of tumors, a group of morphologically
heterogeneous neoplasms that share the same cytogenetic features.
They are considered neural tumors derived from cells of the neural
crest. Ewing sarcoma represents the less differentiated form of
the tumors. {ECO:0000269|PubMed:15044653,
ECO:0000269|PubMed:1522903, ECO:0000269|PubMed:7700648,
ECO:0000269|PubMed:9121764}. Note=The protein represented in this
entry is involved in disease pathogenesis. Chromosomal aberrations
involving EWSR1 are found in patients with Ewing sarcoma.
Translocation t(11;22)(q24;q12) with FLI1 (PubMed:1522903,
PubMed:15044653). Translocation t(7;22)(p22;q12) with ETV1
(PubMed:7700648). Translocation t(21;22)(q22;q21) with ERG
(PubMed:15044653). Translocation t(2;21;22)(q23;q22;q12) that
forms a EWSR1-FEV fusion protein with potential oncogenic activity
(PubMed:9121764). {ECO:0000269|PubMed:15044653,
ECO:0000269|PubMed:1522903, ECO:0000269|PubMed:7700648,
ECO:0000269|PubMed:9121764}.
-!- DISEASE: Note=A chromosomal aberration involving EWSR1 has been
found in extraskeletal myxoid chondrosarcoma. Translocation
t(9;22)(q22-31;q11-12) with NR4A3. {ECO:0000269|PubMed:7539287}.
-!- DISEASE: Note=A chromosomal aberration involving EWSR1 is
associated with desmoplastic small round cell tumor (DSRCT).
Translocation t(11;22)(p13;q12) with WT1.
{ECO:0000269|PubMed:7862627}.
-!- DISEASE: Note=A chromosomal aberration involving EWSR1 is
associated with malignant melanoma of soft parts (MMSP).
Translocation t(12;22)(q13;q12) with ATF1. Malignant melanoma of
soft parts, also known as soft tissue clear cell sarcoma, is a
rare tumor developing in tendons and aponeuroses.
{ECO:0000269|PubMed:8401579}.
-!- DISEASE: Note=A chromosomal aberration involving EWSR1 is
associated with small round cell sarcoma. Translocation
t(11;22)(p36.1;q12) with PATZ1. {ECO:0000269|PubMed:10949935}.
-!- DISEASE: Angiomatoid fibrous histiocytoma (AFH) [MIM:612160]: A
distinct variant of malignant fibrous histiocytoma that typically
occurs in children and adolescents and is manifest by nodular
subcutaneous growth. Characteristic microscopic features include
lobulated sheets of histiocyte-like cells intimately associated
with areas of hemorrhage and cystic pseudovascular spaces, as well
as a striking cuffing of inflammatory cells, mimicking a lymph
node metastasis. {ECO:0000269|PubMed:15884099,
ECO:0000269|PubMed:17724745}. Note=The gene represented in this
entry is involved in disease pathogenesis. Chromosomal aberrations
involving EWSR1 are found in patients with angiomatoid fibrous
histiocytoma. Translocation t(12;22)(q13;q12) with ATF1 generates
a chimeric EWSR1/ATF1 protein (PubMed:15884099). Translocation
t(2;22)(q33;q12) with CREB1 generates a EWSR1/CREB1 fusion gene
that is most common genetic abnormality in this tumor type
(PubMed:17724745). {ECO:0000269|PubMed:15884099,
ECO:0000269|PubMed:17724745}.
-!- DISEASE: Note=EFPS arise due to chromosomal translocations in
which EWSR1 is fused to a variety of cellular transcription
factors. EFPS are very potent transcriptional activators dependent
on the EAD and a C-terminal DNA-binding domain contributed by the
fusion partner. The spectrum of malignancies associated with EFPS
are thought to arise via EFP-induced transcriptional deregulation,
with the tumor phenotype specified by the EWSR1 fusion partner and
cell type. Transcriptional repression of the transforming growth
factor beta type II receptor (TGF beta RII) is an important target
of the EWS-FLI1, EWS-ERG, or EWS-ETV1 oncogene. {ECO:0000305}.
-!- SIMILARITY: Belongs to the RRM TET family. {ECO:0000305}.
-!- SEQUENCE CAUTION:
Sequence=CAA70044.1; Type=Erroneous initiation; Evidence={ECO:0000305};
-!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
and Haematology;
URL="http://atlasgeneticsoncology.org/Genes/EWSR1ID85.html";
-----------------------------------------------------------------------
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
-----------------------------------------------------------------------
EMBL; X66899; CAA47350.1; -; mRNA.
EMBL; X72990; CAA51489.1; -; Genomic_DNA.
EMBL; X72991; CAA51489.1; JOINED; Genomic_DNA.
EMBL; X72992; CAA51489.1; JOINED; Genomic_DNA.
EMBL; X72993; CAA51489.1; JOINED; Genomic_DNA.
EMBL; X72994; CAA51489.1; JOINED; Genomic_DNA.
EMBL; X72995; CAA51489.1; JOINED; Genomic_DNA.
EMBL; X72996; CAA51489.1; JOINED; Genomic_DNA.
EMBL; X72997; CAA51489.1; JOINED; Genomic_DNA.
EMBL; X72998; CAA51489.1; JOINED; Genomic_DNA.
EMBL; X72999; CAA51489.1; JOINED; Genomic_DNA.
EMBL; X73000; CAA51489.1; JOINED; Genomic_DNA.
EMBL; X73001; CAA51489.1; JOINED; Genomic_DNA.
EMBL; X73002; CAA51489.1; JOINED; Genomic_DNA.
EMBL; X73003; CAA51489.1; JOINED; Genomic_DNA.
EMBL; X73004; CAA51489.1; JOINED; Genomic_DNA.
EMBL; Y07848; CAA69177.1; -; Genomic_DNA.
EMBL; CR456490; CAG30376.1; -; mRNA.
EMBL; AK056309; BAB71145.1; -; mRNA.
EMBL; AK056681; BAB71252.1; -; mRNA.
EMBL; AL031186; CAI18001.1; -; Genomic_DNA.
EMBL; AC000026; CAI18001.1; JOINED; Genomic_DNA.
EMBL; AC002059; CAI18001.1; JOINED; Genomic_DNA.
EMBL; AL031186; CAQ10937.1; -; Genomic_DNA.
EMBL; AC000026; CAQ10937.1; JOINED; Genomic_DNA.
EMBL; AC002059; CAQ10937.1; JOINED; Genomic_DNA.
EMBL; AL031186; CAQ10938.1; -; Genomic_DNA.
EMBL; AC000026; CAQ10938.1; JOINED; Genomic_DNA.
EMBL; AC002059; CAQ10938.1; JOINED; Genomic_DNA.
EMBL; AL031186; CAQ10940.1; -; Genomic_DNA.
EMBL; AC000026; CAQ10940.1; JOINED; Genomic_DNA.
EMBL; AC002059; CAQ10940.1; JOINED; Genomic_DNA.
EMBL; CH471095; EAW59780.1; -; Genomic_DNA.
EMBL; CH471095; EAW59781.1; -; Genomic_DNA.
EMBL; CH471095; EAW59785.1; -; Genomic_DNA.
EMBL; CH471095; EAW59786.1; -; Genomic_DNA.
EMBL; CH471095; EAW59787.1; -; Genomic_DNA.
EMBL; BC000527; AAH00527.1; -; mRNA.
EMBL; BC004817; AAH04817.1; -; mRNA.
EMBL; BC011048; AAH11048.1; -; mRNA.
EMBL; BC072442; AAH72442.1; -; mRNA.
EMBL; Y08806; CAA70044.1; ALT_INIT; Genomic_DNA.
EMBL; AB016435; BAA31990.1; -; Genomic_DNA.
CCDS; CCDS13851.1; -. [Q01844-1]
CCDS; CCDS13852.2; -. [Q01844-5]
CCDS; CCDS54512.1; -. [Q01844-4]
CCDS; CCDS54513.1; -. [Q01844-3]
CCDS; CCDS54514.1; -. [Q01844-6]
PIR; A49358; A49358.
RefSeq; NP_001156757.1; NM_001163285.1. [Q01844-3]
RefSeq; NP_001156758.1; NM_001163286.1. [Q01844-6]
RefSeq; NP_001156759.1; NM_001163287.1. [Q01844-4]
RefSeq; NP_005234.1; NM_005243.3. [Q01844-1]
RefSeq; NP_053733.2; NM_013986.3. [Q01844-5]
UniGene; Hs.374477; -.
PDB; 2CPE; NMR; -; A=353-453.
PDBsum; 2CPE; -.
DisProt; DP00632; -.
ProteinModelPortal; Q01844; -.
SMR; Q01844; -.
BioGrid; 108431; 648.
CORUM; Q01844; -.
DIP; DIP-34449N; -.
IntAct; Q01844; 155.
MINT; MINT-4992203; -.
STRING; 9606.ENSP00000400142; -.
iPTMnet; Q01844; -.
PhosphoSitePlus; Q01844; -.
SwissPalm; Q01844; -.
BioMuta; EWSR1; -.
DMDM; 544261; -.
EPD; Q01844; -.
MaxQB; Q01844; -.
PaxDb; Q01844; -.
PeptideAtlas; Q01844; -.
PRIDE; Q01844; -.
DNASU; 2130; -.
Ensembl; ENST00000332035; ENSP00000331699; ENSG00000182944. [Q01844-6]
Ensembl; ENST00000333395; ENSP00000327456; ENSG00000182944. [Q01844-4]
Ensembl; ENST00000397938; ENSP00000381031; ENSG00000182944. [Q01844-1]
Ensembl; ENST00000406548; ENSP00000385726; ENSG00000182944. [Q01844-3]
Ensembl; ENST00000414183; ENSP00000400142; ENSG00000182944. [Q01844-5]
GeneID; 2130; -.
KEGG; hsa:2130; -.
UCSC; uc003aes.5; human. [Q01844-1]
CTD; 2130; -.
DisGeNET; 2130; -.
EuPathDB; HostDB:ENSG00000182944.17; -.
GeneCards; EWSR1; -.
HGNC; HGNC:3508; EWSR1.
HPA; CAB004230; -.
HPA; HPA051771; -.
HPA; HPA062953; -.
MalaCards; EWSR1; -.
MIM; 133450; gene.
MIM; 612160; phenotype.
MIM; 612219; phenotype.
neXtProt; NX_Q01844; -.
OpenTargets; ENSG00000182944; -.
Orphanet; 83469; Desmoplastic small round cell tumor.
Orphanet; 319; Ewing sarcoma.
Orphanet; 370334; Extraskeletal Ewing sarcoma.
Orphanet; 209916; Extraskeletal myxoid chondrosarcoma.
Orphanet; 97338; Melanoma of soft parts.
PharmGKB; PA27921; -.
eggNOG; KOG1995; Eukaryota.
eggNOG; ENOG4111Q2F; LUCA.
GeneTree; ENSGT00530000063105; -.
HOGENOM; HOG000038010; -.
HOVERGEN; HBG000970; -.
InParanoid; Q01844; -.
KO; K13209; -.
OMA; FAWRMEC; -.
OrthoDB; EOG091G0U8W; -.
PhylomeDB; Q01844; -.
TreeFam; TF322599; -.
SIGNOR; Q01844; -.
ChiTaRS; EWSR1; human.
EvolutionaryTrace; Q01844; -.
GeneWiki; Ewing_sarcoma_breakpoint_region_1; -.
GenomeRNAi; 2130; -.
PRO; PR:Q01844; -.
Proteomes; UP000005640; Chromosome 22.
Bgee; ENSG00000182944; -.
CleanEx; HS_EWSR1; -.
ExpressionAtlas; Q01844; baseline and differential.
Genevisible; Q01844; HS.
GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
GO; GO:0005730; C:nucleolus; IDA:HPA.
GO; GO:0005634; C:nucleus; IDA:HPA.
GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
GO; GO:0005516; F:calmodulin binding; IEA:UniProtKB-KW.
GO; GO:0042802; F:identical protein binding; IPI:IntAct.
GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-KW.
GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
CDD; cd12533; RRM_EWS; 1.
InterPro; IPR034869; EWS_RRM.
InterPro; IPR033109; EWSR1.
InterPro; IPR035979; RBD_domain_sf.
InterPro; IPR000504; RRM_dom.
InterPro; IPR034870; TET_fam.
InterPro; IPR001876; Znf_RanBP2.
InterPro; IPR036443; Znf_RanBP2_sf.
PANTHER; PTHR23238; PTHR23238; 1.
PANTHER; PTHR23238:SF3; PTHR23238:SF3; 1.
Pfam; PF00076; RRM_1; 1.
Pfam; PF00641; zf-RanBP; 1.
SMART; SM00360; RRM; 1.
SMART; SM00547; ZnF_RBZ; 1.
SUPFAM; SSF54928; SSF54928; 1.
SUPFAM; SSF90209; SSF90209; 1.
PROSITE; PS50102; RRM; 1.
PROSITE; PS01358; ZF_RANBP2_1; 1.
PROSITE; PS50199; ZF_RANBP2_2; 1.
1: Evidence at protein level;
3D-structure; Acetylation; Alternative splicing; Calmodulin-binding;
Cell membrane; Chromosomal rearrangement; Complete proteome;
Cytoplasm; Direct protein sequencing; Membrane; Metal-binding;
Methylation; Nucleus; Phosphoprotein; Proto-oncogene;
Reference proteome; Repeat; Repressor; RNA-binding; Transcription;
Transcription regulation; Zinc; Zinc-finger.
CHAIN 1 656 RNA-binding protein EWS.
/FTId=PRO_0000081586.
REPEAT 8 16 1.
REPEAT 17 27 2.
REPEAT 28 34 3.
REPEAT 35 42 4.
REPEAT 43 50 5.
REPEAT 51 59 6.
REPEAT 60 68 7.
REPEAT 69 75 8.
REPEAT 76 84 9.
REPEAT 85 91 10.
REPEAT 92 110 11.
REPEAT 111 116 12.
REPEAT 117 125 13.
REPEAT 126 156 14.
REPEAT 157 163 15.
REPEAT 164 170 16.
REPEAT 171 177 17.
REPEAT 178 188 18.
REPEAT 189 193 19.
REPEAT 194 201 20.
REPEAT 202 206 21.
REPEAT 207 212 22.
REPEAT 213 218 23.
REPEAT 219 224 24.
REPEAT 225 230 25.
REPEAT 231 238 26.
REPEAT 239 245 27.
REPEAT 246 252 28.
REPEAT 253 259 29.
DOMAIN 256 285 IQ.
REPEAT 260 276 30.
REPEAT 277 285 31.
DOMAIN 361 447 RRM. {ECO:0000255|PROSITE-
ProRule:PRU00176}.
ZN_FING 518 549 RanBP2-type. {ECO:0000255|PROSITE-
ProRule:PRU00322}.
REGION 1 285 EAD (Gln/Pro/Thr-rich).
REGION 8 285 31 X approximate tandem repeats.
MOTIF 639 656 Nuclear localization signal.
{ECO:0000269|PubMed:16965792}.
COMPBIAS 300 340 Arg/Gly/Pro-rich.
COMPBIAS 454 513 Arg/Gly/Pro-rich.
COMPBIAS 559 640 Arg/Gly/Pro-rich.
SITE 265 265 Breakpoint for translocation to form
chimeric EWSR1/ATF1 protein.
SITE 348 349 Breakpoint for insertion to form EWSR1-
FEV fusion protein.
MOD_RES 266 266 Phosphoserine; by PKC. {ECO:0000250}.
MOD_RES 300 300 Asymmetric dimethylarginine.
{ECO:0000269|PubMed:11278906}.
MOD_RES 302 302 Asymmetric dimethylarginine.
{ECO:0000269|PubMed:11278906}.
MOD_RES 304 304 Asymmetric dimethylarginine.
{ECO:0000269|PubMed:11278906}.
MOD_RES 309 309 Asymmetric dimethylarginine.
{ECO:0000269|PubMed:11278906}.
MOD_RES 314 314 Asymmetric dimethylarginine.
{ECO:0000269|PubMed:11278906}.
MOD_RES 317 317 Asymmetric dimethylarginine.
{ECO:0000269|PubMed:11278906}.
MOD_RES 321 321 Asymmetric dimethylarginine.
{ECO:0000269|PubMed:11278906}.
MOD_RES 439 439 N6-acetyllysine.
{ECO:0000250|UniProtKB:Q61545}.
MOD_RES 455 455 Asymmetric dimethylarginine.
{ECO:0000269|PubMed:11278906}.
MOD_RES 464 464 Asymmetric dimethylarginine.
{ECO:0000269|PubMed:11278906}.
MOD_RES 471 471 Asymmetric dimethylarginine; alternate.
{ECO:0000269|PubMed:11278906}.
MOD_RES 471 471 Omega-N-methylarginine; alternate.
{ECO:0000244|PubMed:24129315,
ECO:0000269|PubMed:11278906}.
MOD_RES 486 486 Omega-N-methylarginine.
{ECO:0000244|PubMed:24129315}.
MOD_RES 490 490 Asymmetric dimethylarginine; by PRMT8.
{ECO:0000269|PubMed:11278906,
ECO:0000269|PubMed:18320585}.
MOD_RES 494 494 Asymmetric dimethylarginine.
{ECO:0000269|PubMed:11278906,
ECO:0000269|Ref.12}.
MOD_RES 500 500 Asymmetric dimethylarginine.
{ECO:0000269|PubMed:11278906}.
MOD_RES 503 503 Asymmetric dimethylarginine.
{ECO:0000269|PubMed:11278906}.
MOD_RES 506 506 Asymmetric dimethylarginine; alternate.
{ECO:0000269|PubMed:11278906}.
MOD_RES 506 506 Omega-N-methylarginine; alternate.
{ECO:0000250|UniProtKB:Q61545}.
MOD_RES 563 563 Asymmetric dimethylarginine.
{ECO:0000269|PubMed:11278906}.
MOD_RES 565 565 Asymmetric dimethylarginine.
{ECO:0000269|PubMed:11278906}.
MOD_RES 572 572 Asymmetric dimethylarginine; alternate;
by PRMT8. {ECO:0000269|PubMed:11278906,
ECO:0000269|PubMed:18320585}.
MOD_RES 572 572 Omega-N-methylarginine; alternate; by
PRMT8. {ECO:0000269|PubMed:11278906,
ECO:0000269|PubMed:18320585}.
MOD_RES 575 575 Asymmetric dimethylarginine.
{ECO:0000269|PubMed:11278906}.
MOD_RES 581 581 Asymmetric dimethylarginine.
{ECO:0000269|PubMed:11278906}.
MOD_RES 589 589 Asymmetric dimethylarginine.
{ECO:0000269|PubMed:11278906}.
MOD_RES 592 592 Asymmetric dimethylarginine.
{ECO:0000269|PubMed:11278906}.
MOD_RES 596 596 Asymmetric dimethylarginine; alternate;
by PRMT8. {ECO:0000269|PubMed:11278906,
ECO:0000269|PubMed:18320585}.
MOD_RES 596 596 Omega-N-methylarginine; alternate; by
PRMT8. {ECO:0000269|PubMed:11278906,
ECO:0000269|PubMed:18320585}.
MOD_RES 600 600 Asymmetric dimethylarginine.
{ECO:0000269|PubMed:11278906}.
MOD_RES 603 603 Asymmetric dimethylarginine; by PRMT8.
{ECO:0000269|PubMed:11278906,
ECO:0000269|PubMed:18320585}.
MOD_RES 607 607 Asymmetric dimethylarginine; alternate;
by PRMT8. {ECO:0000269|PubMed:11278906,
ECO:0000269|PubMed:18320585}.
MOD_RES 607 607 Omega-N-methylarginine; alternate; by
PRMT8. {ECO:0000269|PubMed:11278906,
ECO:0000269|PubMed:18320585}.
MOD_RES 615 615 Asymmetric dimethylarginine; alternate.
{ECO:0000269|PubMed:11278906,
ECO:0000269|Ref.12}.
MOD_RES 615 615 Omega-N-methylarginine; alternate.
{ECO:0000244|PubMed:24129315}.
MOD_RES 633 633 Asymmetric dimethylarginine.
{ECO:0000269|PubMed:11278906}.
MOD_RES 636 636 Asymmetric dimethylarginine.
{ECO:0000269|PubMed:11278906}.
VAR_SEQ 74 74 P -> PTVEGTS (in isoform 5).
{ECO:0000303|PubMed:14702039}.
/FTId=VSP_043451.
VAR_SEQ 136 191 Missing (in isoform 6).
{ECO:0000303|PubMed:14702039}.
/FTId=VSP_045412.
VAR_SEQ 266 338 Missing (in isoform EWS-B).
{ECO:0000305}.
/FTId=VSP_005793.
VAR_SEQ 326 354 SAGERGGFNKPGGPMDEGPDLDLGPPVDP -> LQSESLVY
TSILKKYPYSVLSRQHNEKWD (in isoform 4).
{ECO:0000303|PubMed:15489334}.
/FTId=VSP_043452.
VAR_SEQ 326 326 Missing (in isoform 3 and isoform 5).
{ECO:0000303|PubMed:14702039,
ECO:0000303|PubMed:15461802,
ECO:0000303|PubMed:15489334}.
/FTId=VSP_043453.
VAR_SEQ 355 656 Missing (in isoform 4).
{ECO:0000303|PubMed:15489334}.
/FTId=VSP_043454.
MUTAGEN 648 648 R->A: Cytoplasmic localization.
{ECO:0000269|PubMed:16965792}.
MUTAGEN 648 648 R->K: No effect on nuclear targeting.
{ECO:0000269|PubMed:16965792}.
MUTAGEN 651 651 R->A: No effect on nuclear targeting.
{ECO:0000269|PubMed:16965792}.
MUTAGEN 652 652 R->A: Cytoplasmic localization.
{ECO:0000269|PubMed:16965792}.
MUTAGEN 652 652 R->K: No effect on nuclear targeting.
{ECO:0000269|PubMed:16965792}.
MUTAGEN 653 653 D->A: No effect on nuclear targeting.
{ECO:0000269|PubMed:16965792}.
MUTAGEN 654 654 R->A: No effect on nuclear targeting.
{ECO:0000269|PubMed:16965792}.
MUTAGEN 655 655 P->A: Cytoplasmic localization.
{ECO:0000269|PubMed:16965792}.
MUTAGEN 656 656 Y->A: Cytoplasmic localization.
{ECO:0000269|PubMed:16965792}.
CONFLICT 224 224 S -> G (in Ref. 5; BAB71252).
{ECO:0000305}.
STRAND 362 366 {ECO:0000244|PDB:2CPE}.
HELIX 374 381 {ECO:0000244|PDB:2CPE}.
TURN 382 384 {ECO:0000244|PDB:2CPE}.
STRAND 391 393 {ECO:0000244|PDB:2CPE}.
STRAND 396 399 {ECO:0000244|PDB:2CPE}.
TURN 404 406 {ECO:0000244|PDB:2CPE}.
STRAND 411 419 {ECO:0000244|PDB:2CPE}.
HELIX 420 430 {ECO:0000244|PDB:2CPE}.
STRAND 441 443 {ECO:0000244|PDB:2CPE}.
SEQUENCE 656 AA; 68478 MW; 0DA02CEE146720BB CRC64;
MASTDYSTYS QAAAQQGYSA YTAQPTQGYA QTTQAYGQQS YGTYGQPTDV SYTQAQTTAT
YGQTAYATSY GQPPTGYTTP TAPQAYSQPV QGYGTGAYDT TTATVTTTQA SYAAQSAYGT
QPAYPAYGQQ PAATAPTRPQ DGNKPTETSQ PQSSTGGYNQ PSLGYGQSNY SYPQVPGSYP
MQPVTAPPSY PPTSYSSTQP TSYDQSSYSQ QNTYGQPSSY GQQSSYGQQS SYGQQPPTSY
PPQTGSYSQA PSQYSQQSSS YGQQSSFRQD HPSSMGVYGQ ESGGFSGPGE NRSMSGPDNR
GRGRGGFDRG GMSRGGRGGG RGGMGSAGER GGFNKPGGPM DEGPDLDLGP PVDPDEDSDN
SAIYVQGLND SVTLDDLADF FKQCGVVKMN KRTGQPMIHI YLDKETGKPK GDATVSYEDP
PTAKAAVEWF DGKDFQGSKL KVSLARKKPP MNSMRGGLPP REGRGMPPPL RGGPGGPGGP
GGPMGRMGGR GGDRGGFPPR GPRGSRGNPS GGGNVQHRAG DWQCPNPGCG NQNFAWRTEC
NQCKAPKPEG FLPPPFPPPG GDRGRGGPGG MRGGRGGLMD RGGPGGMFRG GRGGDRGGFR
GGRGMDRGGF GGGRRGGPGG PPGPLMEQMG GRRGGRGGPG KMDKGEHRQE RRDRPY


Related products :

Catalog number Product name Quantity
15-288-21286A RNA-binding protein EWS - EWS oncogene; Ewing sarcoma breakpoint region 1 protein Polyclonal 0.05 mg
15-288-21286A RNA-binding protein EWS - EWS oncogene; Ewing sarcoma breakpoint region 1 protein Polyclonal 0.1 mg
EIAAB13432 Ewing sarcoma breakpoint region 1 protein,EWS,EWS oncogene,EWSR1,Homo sapiens,Human,RNA-binding protein EWS
EXD2 EWSR1 Gene Ewing sarcoma breakpoint region 1
CSB-EL007875HU Human Ewing sarcoma breakpoint region 1 (EWSR1) ELISA kit, Species Human, Sample Type serum, plasma 96T
CSB-EL007875MO Mouse Ewing sarcoma breakpoint region 1 (EWSR1) ELISA kit, Species Mouse, Sample Type serum, plasma 96T
CSB-PA007875GA01HU Rabbit anti-human Ewing sarcoma breakpoint region 1 polyclonal Antibody Primary antibody Host:Rabbit IgG 150ul
CSB-PA007875GA01HU Rabbit anti-human Ewing sarcoma breakpoint region 1 polyclonal Antibody Primary antibody Host:Rabbit IgG 50ul
20-272-191387 CD99 Ewing Sarcoma - Mouse monoclonal [HO36-1.1] to CD99 Ewing Sarcoma; T-cell surface glycoprotein E2; E2 antigen; Protein MIC2; 12E7 Monoclonal 0.5 ml
29-414 EWSR1 is a putative RNA binding protein. Mutations in this gene, specifically a t (11;22) (q24;q12) translocation, are known to cause Ewing sarcoma as well as neuroectodermal and various other tumors. 0.05 mg
201-20-5597 SSX2IP{synovial sarcoma, X breakpoint 2 interacting protein}rabbit.pAb 0.2ml
EIAAB14724 Feline sarcoma_Fujinami avian sarcoma oncogene homolog,FES,FPS,Homo sapiens,Human,p93c-fes,Proto-oncogene c-Fes,Proto-oncogene c-Fps,Tyrosine-protein kinase Fes_Fps
18-785-210089 c-Jun (Ab-93) - Activator protein 1; AP1; Proto-oncogene c-jun; V-jun avian sarcoma virus 17 oncogene homolog; p39 Polyclonal 0.1 mg
18-785-210090 c-Jun (Ab-170) - Activator protein 1; AP1; Proto-oncogene c-jun; V-jun avian sarcoma virus 17 oncogene homolog; p39 Polyclonal 0.05 mg
18-785-210089 c-Jun (Ab-93) - Activator protein 1; AP1; Proto-oncogene c-jun; V-jun avian sarcoma virus 17 oncogene homolog; p39 Polyclonal 0.05 mg
18-785-210088 c-Jun (Ab-91) - Activator protein 1; AP1; Proto-oncogene c-jun; V-jun avian sarcoma virus 17 oncogene homolog; p39 Polyclonal 0.1 mg
18-785-210088 c-Jun (Ab-91) - Activator protein 1; AP1; Proto-oncogene c-jun; V-jun avian sarcoma virus 17 oncogene homolog; p39 Polyclonal 0.05 mg
18-785-210087 c-Jun (Ab-73) - Activator protein 1; AP1; Proto-oncogene c-jun; V-jun avian sarcoma virus 17 oncogene homolog; p39 Polyclonal 0.1 mg
18-785-210087 c-Jun (Ab-73) - Activator protein 1; AP1; Proto-oncogene c-jun; V-jun avian sarcoma virus 17 oncogene homolog; p39 Polyclonal 0.05 mg
18-785-210086 c-Jun (Ab-63) - Activator protein 1; AP1; Proto-oncogene c-jun; V-jun avian sarcoma virus 17 oncogene homolog; p39 Polyclonal 0.1 mg
18-785-210090 c-Jun (Ab-170) - Activator protein 1; AP1; Proto-oncogene c-jun; V-jun avian sarcoma virus 17 oncogene homolog; p39 Polyclonal 0.1 mg
18-785-210091 c-Jun (Ab-243) - Activator protein 1; AP1; Proto-oncogene c-jun; V-jun avian sarcoma virus 17 oncogene homolog; p39 Polyclonal 0.05 mg
18-785-210091 c-Jun (Ab-243) - Activator protein 1; AP1; Proto-oncogene c-jun; V-jun avian sarcoma virus 17 oncogene homolog; p39 Polyclonal 0.1 mg
18-785-210093 c-Jun (Ab-239) - Activator protein 1; AP1; Proto-oncogene c-jun; V-jun avian sarcoma virus 17 oncogene homolog; p39 Polyclonal 0.05 mg
18-785-210086 c-Jun (Ab-63) - Activator protein 1; AP1; Proto-oncogene c-jun; V-jun avian sarcoma virus 17 oncogene homolog; p39 Polyclonal 0.05 mg


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur